Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Aggression in Intermittent Explosive Disorder
NCT05895513Phase 2Recruiting
- Sponsor
- The Ohio State University
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimavanserin in intermittent explosive disorder (IED), sponsored by The Ohio State University. Started Aug 2024; status: recruiting.
02
Drugs
pimavanserin
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT05895513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895513.